{'fraction_non_alphanumeric': 0.023090586145648313, 'fraction_numerical': 0.0, 'mean_word_length': 5.795180722891566, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Monoclonal antibodies in dermatological practice].

The recent approval of several monoclonal antibodies in dermatological treatment in recent years appears to be only only the phase in development of monoclonal antibody therapy for skin diseases. Several analyses point to the growth of the market for these drugs, and forecast an even higher expansion of the use of monoclonal antibodies in dermatologic therapy. The possible application of several monoclonal antibodies, including, adalimumab, efalizumab, infliximab, rituximab, in skin diseases is discussed.